Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Articles
  • Éducation
Campus
  • Articles
  • Éducation

Dyslipidémie

Articles

146 for Lipid Management After ACS

146 for Lipid Management After ACS

Explorer
2024 ESC Guidelines for the management of chronic coronary syndromes

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Explorer
What is PRALUENT<sup>®</sup>?

What is PRALUENT®?

PRALUENT®: a powerful PCSK9i that ticks all the boxes1–4

 

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1

Explorer
Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Explorer
Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer
How to use PRALUENT<sup>®</sup>?

How to use PRALUENT®?

Explorer
Lipid management in patients with diabetes mellitus

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Explorer
Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Explorer